Related Experiment Video
Updated: Jan 10, 2026

Author Spotlight: Unveiling the Connection Between Sleep Disorders and Cognitive Symptoms in Depression
Published on: April 26, 2024
The incidence, prevalence and treatment of narcolepsy in New Zealand
Nathaniel Hutchison-Wong1, Alister Neill1, Angela Campbell1
1WellSleep, Department of Medicine, University of Otago Wellington, Wellington, New Zealand.
Aim:
No previous research has assessed the epidemiology or treatment of narcolepsy in New Zealand. This study aimed to estimate its national incidence and prevalence and examine demographic trends in the prescribing of narcolepsy-related medications.
Method:
From 2021 to 2023, diagnostic data from all centres conducting multiple sleep latency tests (MSLTs) were analysed to estimate incidence and prevalence. Concurrently, data on all special authority (SA) approvals for narcolepsy medications were obtained from Pharmac and analysed by medication type, region, age, gender and ethnicity.
Results:
Among 342 MSLTs, 57 cases of narcolepsy were identified, giving an incidence of 0.36 per 100,000 person-years and a prevalence of 21.9 per 100,000 people. Over the same period, 223 new and 762 total SA applications were approved. The average number of new approvals (74.3 per year) was 3.9 times higher than the number of new diagnoses (19 per year). Demographic variations were observed in the SA data. Generally, methylphenidate hydrochloride was prescribed more than modafinil.
Conclusions:
This is the first national estimate of the incidence and prevalence of narcolepsy in New Zealand. The mismatch between diagnosis and treatment data likely reflects limited diagnostic access, multiple medication use, the existence of imported cases with established diagnoses and the treatment of idiopathic hypersomnolence (IH) under the guise of narcolepsy. Policy and funding changes are needed to improve care access and reporting accuracy.
More Related Videos
08:20Measuring Neural Mechanisms Underlying Sleep-Dependent Memory Consolidation During Naps in Early Childhood
Published on: October 2, 2019
07:54Drug-Induced Sleep Endoscopy DISE with Target Controlled Infusion TCI and Bispectral Analysis in Obstructive Sleep Apnea
Published on: December 6, 2016
Related Concept Videos
Narcolepsy
Sleep-Wake Cycles
NREM Sleep
NREM sleep comprises four progressive stages that seamlessly merge:
Substance Use Disorders Affecting Sleep
Understanding the concepts of physical dependence,...
Management of Insomnia
Prevalence and Incidence
Prevalence indicates the proportion of individuals in a population who have a specific disease or health...
Sedatives and Hypnotics Drugs: Miscellaneous Agents
Melatonin congeners like ramelteon (Rozerem) and tasimelteon (Hetlioz) selectively bind to melatonin receptors (MT1 and MT2) and thus mimic the actions of melatonin, a hormone that regulates sleep-wake cycles. Tasimelteon is primarily used for non-24-hour sleep-wake disorder, common in blind patients. They are also used to treat conditions like insomnia...